🚚 Free shipping on all orders above $299 · 30 days money back guarantee · Helpline +1 251-332-4105

Afatinib 30 mg

$136.00$4.86 per tablet · 28 tablets
(2 customer reviews)
Choose pack sizePrice per tablet shown

Want to order in bulk / B2B price?

Tracked, discreet delivery

Ships in plain packaging with a tracking number. Delivery time for this product: 6 to 15 days. Free shipping on orders above $299.

30 days money back guarantee

Damaged, missing or only part of your order arrived? Choose a new package or a full refund.

Questions before you order?

Call +1 251-332-4105 or email [email protected].

SECURE CHECKOUT
DISCOVER
MasterCard
VISA

Share

This description covers afatinib 30 mg tablets. Confirm the manufacturer, formulation, pack size, regulatory status, and country-specific approved indications before publishing.

Afatinib is a prescription targeted anticancer medicine that can cause severe diarrhea, dehydration, kidney injury, serious skin reactions, interstitial lung disease, liver injury, eye complications, and fetal harm. Treatment requires specialist oncology supervision.

What Is Afatinib 30 mg?

Afatinib 30 mg is an oral targeted anticancer medicine belonging to the tyrosine kinase inhibitor class.

It is used in selected treatment regimens for non-small cell lung cancer, particularly tumors with susceptible mutations in the epidermal growth factor receptor (EGFR) gene.

Afatinib irreversibly inhibits several members of the ErbB receptor family, including EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4).

These receptors participate in cellular signaling pathways that regulate cell growth, division, and survival.

Certain EGFR mutations cause abnormal signaling that encourages cancer cell proliferation.

Afatinib blocks these pathways and may slow tumor growth in patients whose cancers are sensitive to the medicine.

Unlike conventional cytotoxic chemotherapy, afatinib is a molecularly targeted therapy.

The 30 mg strength is commonly used when a reduced dose is required, particularly after treatment-related adverse effects. It may also be used as an individualized starting dose in certain clinical circumstances, such as severe renal impairment, according to applicable prescribing guidance.

The appropriate dose must always be determined by an oncology specialist.

Common Reasons for Prescribing Afatinib 30 mg

  • EGFR mutation-positive non-small cell lung cancer
  • Selected metastatic NSCLC with susceptible EGFR mutations
  • EGFR exon 19 deletion-positive lung cancer
  • EGFR exon 21 L858R mutation-positive lung cancer
  • Certain uncommon EGFR mutation-positive lung cancers
  • Selected previously treated metastatic squamous NSCLC
  • Dose reduction following treatment-related toxicity
  • Individualized targeted anticancer treatment

Important: Afatinib is not suitable for every lung cancer. Molecular testing and clinical assessment are important when selecting EGFR-targeted treatment.

How Does Afatinib 30 mg Work?

1. Targets the ErbB Receptor Family

Afatinib inhibits several members of the ErbB family of receptor tyrosine kinases.

These include EGFR, HER2, and HER4.

2. Irreversibly Blocks Tyrosine Kinase Activity

Afatinib forms covalent bonds with its target receptors, resulting in irreversible inhibition of their kinase activity.

3. Inhibits Abnormal EGFR Signaling

Certain EGFR mutations activate signaling pathways that promote cancer cell growth.

Afatinib inhibits signaling through susceptible mutant EGFR receptors.

4. Reduces Cancer Cell Proliferation

Blocking ErbB signaling can reduce the ability of susceptible tumor cells to multiply.

5. Interferes With Cancer Cell Survival

Afatinib disrupts pathways involved in tumor cell survival and may promote cancer cell death.

6. Helps Control Tumor Growth

In responsive tumors, afatinib may reduce tumor size or delay disease progression.

7. Provides Molecularly Targeted Treatment

Afatinib is selected according to the tumor’s molecular characteristics and the patient’s clinical circumstances.

8. Supports Disease Management

When effective and tolerated, afatinib may help control metastatic NSCLC over time.

Important: Afatinib is not effective against every EGFR mutation. Some resistance mutations and molecular alterations require different treatment approaches.

Uses of Afatinib 30 mg

1. EGFR Mutation-Positive Non-Small Cell Lung Cancer

Afatinib is used in selected patients with EGFR mutation-positive NSCLC.

Its effectiveness depends on the specific mutation and clinical setting.

2. Metastatic Non-Small Cell Lung Cancer

Afatinib has approved indications in certain jurisdictions for metastatic NSCLC with susceptible EGFR mutations.

3. EGFR Exon 19 Deletion-Positive NSCLC

Certain EGFR exon 19 deletions are associated with sensitivity to EGFR tyrosine kinase inhibitors, including afatinib.

4. EGFR L858R Mutation-Positive NSCLC

Afatinib may be used for selected patients whose tumors contain the EGFR exon 21 L858R substitution.

5. Selected Uncommon EGFR Mutations

Afatinib has demonstrated activity against certain uncommon EGFR mutations, including G719X, L861Q, and S768I.

The exact molecular findings should be reviewed by an oncology specialist.

6. Previously Treated Metastatic Squamous NSCLC

In the United States, afatinib has an approved indication for metastatic squamous NSCLC that has progressed after platinum-based chemotherapy.

Its clinical role depends on treatment history and available alternatives.

7. Molecularly Guided Cancer Therapy

Afatinib may be selected based on molecular testing results and current treatment recommendations.

8. Disease Progression Control

In responsive patients, afatinib may delay cancer progression.

9. Tumor Burden Reduction

Afatinib may reduce tumor size in certain susceptible cancers.

10. Dose-Adjusted Targeted Treatment

Afatinib 30 mg may be prescribed when an oncologist determines that a lower dose is appropriate because of adverse effects or other clinical considerations.

Important: Modern EGFR-targeted treatment options have evolved, and other agents may be preferred for many patients depending on the mutation and treatment setting.

Afatinib 30 mg Dosage and Administration

Afatinib dosing must be determined by an oncology specialist.

General Dosage Information

Dosage InformationDetails
Tablet Strength30 mg
Active IngredientAfatinib
Administration RouteOral
Usual Adult Starting Dose40 mg once daily for certain approved indications
30 mg Tablet RoleCommon dose-reduction strength; may be used initially in selected patients
Administration FrequencyUsually once daily
Food InstructionsTake on an empty stomach
Treatment DurationUntil disease progression or unacceptable toxicity, as directed
Dose AdjustmentsBased on adverse reactions, kidney function, and other clinical factors
Other Available Strengths20 mg and 40 mg; availability varies by market
Medical SupervisionRequired throughout treatment

Important: Afatinib 30 mg is not automatically the standard starting dose. A common starting dose for certain approved adult indications is 40 mg once daily. Patients with severe renal impairment may require a 30 mg starting dose under the applicable product labeling.

General Administration Instructions

  1. Take afatinib exactly as prescribed by the oncologist.
  2. Take the medicine at approximately the same time each day.
  3. Swallow the tablet whole with water.
  4. Take it on an empty stomach.
  5. Avoid eating for at least 3 hours before and 1 hour after taking the dose.
  6. Do not crush or chew the tablet.
  7. Do not increase or reduce the dose independently.
  8. Report diarrhea promptly.
  9. Monitor for new breathing difficulties.
  10. Report severe skin reactions or painful mouth sores.
  11. Attend scheduled medical appointments and laboratory tests.
  12. Inform the healthcare team about other medicines and supplements.

Should Afatinib 30 mg Be Taken With Food?

Afatinib should generally be taken on an empty stomach.

Food can reduce afatinib exposure.

The reference instructions recommend avoiding food for at least 3 hours before and 1 hour after the dose.

What If a Dose Is Missed?

According to reference afatinib prescribing information, a missed dose may be taken if the next scheduled dose is more than 12 hours away.

If the next dose is within 12 hours, skip the missed dose.

Do not take two doses together.

What If Too Much Afatinib Is Taken?

Contact the oncology team or seek urgent medical advice.

An overdose may increase the risk of severe gastrointestinal and other adverse effects.

Can Afatinib Be Stopped Suddenly?

Do not independently stop or change the treatment.

The oncology team may interrupt, reduce, or discontinue afatinib because of adverse effects, disease progression, or other clinical considerations.

How Long Does Afatinib 30 mg Take to Work?

Afatinib begins inhibiting its molecular targets after absorption.

However, measurable treatment responses usually require time.

An oncologist may evaluate the response using imaging studies and clinical assessments after several weeks of treatment.

The time required depends on the tumor’s mutation profile, disease burden, and individual response.

Some patients may notice improvement in cancer-related symptoms before formal imaging confirms a response.

However, symptom improvement alone does not establish treatment effectiveness.

Common Side Effects

Possible side effects include:

  • Diarrhea
  • Acne-like skin rash
  • Dry skin
  • Itching
  • Mouth sores
  • Stomatitis
  • Reduced appetite
  • Nausea
  • Vomiting
  • Nail inflammation
  • Paronychia
  • Fatigue
  • Weight loss
  • Nosebleeds
  • Abdominal discomfort

Diarrhea and skin reactions are particularly important adverse effects of afatinib.

Potentially Harmful Effects & Serious Health Risks

1. Severe Diarrhea

Afatinib can cause severe or persistent diarrhea.

This may lead to dehydration, electrolyte abnormalities, and hospitalization.

2. Dehydration

Significant fluid loss from diarrhea or vomiting can cause dehydration.

3. Acute Kidney Injury

Severe dehydration may contribute to acute kidney injury.

4. Severe Skin Reactions

Afatinib may cause serious skin reactions, including severe acneiform rash and blistering.

5. Interstitial Lung Disease

Afatinib can cause interstitial lung disease or pneumonitis, which may be life-threatening.

6. Liver Injury

Afatinib may cause elevated liver enzymes and serious liver injury.

7. Severe Stomatitis

Painful mouth ulcers and inflammation may interfere with eating and drinking.

8. Eye Complications

Keratitis and other ocular complications may occur.

9. Cardiac Dysfunction

Decreased left ventricular ejection fraction has been reported.

10. Electrolyte Disturbances

Severe diarrhea and dehydration may cause electrolyte imbalances.

11. Severe Nail Inflammation

Paronychia may cause painful swelling or infection around the nails.

12. Fetal Harm

Afatinib may harm an unborn baby.

Severe adverse reactions may require dose interruption, reduction, or permanent discontinuation.

14. Serious Hypersensitivity

Allergic reactions may occur.

Emergency warning: Seek urgent medical assessment for new or worsening shortness of breath, severe persistent diarrhea, dehydration, blistering skin reactions, severe eye pain, or symptoms of liver injury.

Contraindications & Safety Precautions

1. Hypersensitivity to Afatinib

Patients with known hypersensitivity to afatinib or its ingredients require specialist assessment and should not continue the medicine after a serious allergic reaction.

2. Severe Diarrhea

Report diarrhea promptly because dehydration and kidney complications may develop.

3. Dehydration Risk

Maintain adequate hydration according to medical instructions.

4. Kidney Disease

Kidney function should be assessed before treatment and monitored when appropriate.

5. Severe Renal Impairment

Patients with severe kidney impairment may require a reduced starting dose.

6. Liver Disease

Patients with liver impairment require appropriate monitoring.

7. Interstitial Lung Disease

New cough, fever, or worsening breathlessness may indicate serious pulmonary toxicity.

8. Skin Disorders

Report severe or worsening rash, blistering, or painful skin changes.

9. Sun Exposure

Sun exposure may worsen certain afatinib-associated skin reactions.

Appropriate sun protection may be recommended.

10. Eye Problems

Report eye pain, redness, light sensitivity, excessive tearing, or vision changes.

11. Heart Disease

Patients with cardiac disease may require additional monitoring.

12. Pregnancy

Afatinib can cause fetal harm.

Patients who are pregnant or planning pregnancy should discuss treatment risks with their oncology specialist.

13. Contraception

Patients who can become pregnant should use effective contraception during treatment and for the period specified in the approved product labeling after the final dose.

14. Breastfeeding

Breastfeeding is not recommended during treatment and for the period specified by the applicable product label after treatment.

15. Children

The safety and effectiveness of afatinib have not been established for routine pediatric use.

16. Older Adults

Older adults may require closer monitoring because of adverse effects and coexisting medical conditions.

17. Drug Interactions

Potentially important interactions include:

  • P-glycoprotein (P-gp) Inhibitors: May increase afatinib exposure.
  • P-gp Inducers: May reduce afatinib exposure.
  • Rifampicin: May reduce afatinib concentrations.
  • Certain Antifungals: Some may affect afatinib exposure through transporter interactions.
  • Certain Antibiotics: Some may affect drug transporter activity.
  • Other Anticancer Medicines: Require specialist review.
  • Herbal Supplements: May affect drug exposure or tolerability.

18. Food Interactions

Afatinib should be taken on an empty stomach according to the product instructions.

19. Medical Monitoring

Healthcare professionals may monitor:

  • Kidney function
  • Liver function
  • Electrolytes
  • Diarrhea severity
  • Hydration status
  • Skin reactions
  • Mouth inflammation
  • Eye symptoms
  • Pulmonary symptoms
  • Cardiac function when indicated
  • Body weight
  • Treatment response
  • Imaging findings
  • Need for dose reduction or interruption

Advantages

  • Oral targeted anticancer therapy.
  • Irreversible ErbB family inhibition.
  • Activity against selected EGFR-mutated NSCLC.
  • Used in certain metastatic lung cancer treatment regimens.
  • Activity against some uncommon EGFR mutations.
  • May help delay disease progression in responsive tumors.
  • May reduce tumor burden.
  • Does not require intravenous administration.
  • Once-daily administration.
  • 30 mg strength supports individualized dose adjustments.
  • Established clinical evidence for selected indications.
  • May be continued while clinically effective and tolerable.

Disadvantages / Limitations

  • Not effective against every lung cancer.
  • Requires molecular testing for many indications.
  • May cause severe diarrhea.
  • May cause dehydration.
  • May cause kidney injury.
  • May cause severe skin rash.
  • May cause mouth ulcers.
  • May cause nail inflammation.
  • May cause reduced appetite.
  • May cause weight loss.
  • May cause liver injury.
  • May cause interstitial lung disease.
  • May cause eye complications.
  • May affect cardiac function.
  • Can harm an unborn baby.
  • Requires oncology monitoring.
  • May interact with certain medicines.
  • Must be taken on an empty stomach.
  • May require further dose reduction.
  • Resistance to treatment can develop.
  • Newer targeted therapies may be preferred in certain settings.

Important Notes

Generic Name: Afatinib.

Strength: 30 mg.

Drug Class: Tyrosine Kinase Inhibitor.

Therapeutic Category: Targeted Anticancer Medicine.

Primary Use: Selected EGFR mutation-positive NSCLC.

Additional Use: Selected previously treated metastatic squamous NSCLC.

Mechanism: Irreversible inhibition of ErbB receptor tyrosine kinases.

Administration Route: Oral.

Usual Adult Starting Dose: 40 mg once daily for certain approved indications.

30 mg Strength: Commonly used for dose reduction or selected individualized starting regimens.

Food Instructions: Take on an empty stomach.

Major Warning: Severe diarrhea, dehydration, skin reactions, interstitial lung disease, liver injury, and fetal harm.

Pregnancy Warning: Can cause fetal harm.

Breastfeeding Warning: Not recommended during treatment.

Monitoring: Kidney function, liver function, hydration, adverse effects, and treatment response.

Prescription Status: Prescription-Only Anticancer Medicine.

Storage: Follow manufacturer instructions.

Frequently Asked Questions

1. What is Afatinib 30 mg used for?

Afatinib 30 mg is a targeted anticancer medicine used in selected treatment regimens for non-small cell lung cancer, particularly tumors with susceptible EGFR mutations.

2. Is Afatinib a chemotherapy medicine?

Afatinib is a targeted anticancer medicine, not conventional cytotoxic chemotherapy.

3. How does Afatinib work?

It irreversibly inhibits certain ErbB family receptor tyrosine kinases, reducing growth and survival signaling in susceptible cancer cells.

4. Can Afatinib treat lung cancer?

Yes. It is used for selected forms of non-small cell lung cancer.

5. Does Afatinib work for every EGFR mutation?

No. Its effectiveness depends on the specific mutation, and some mutations are resistant.

6. Is Afatinib 30 mg the standard starting dose?

Not usually. A common starting dose for certain approved adult indications is 40 mg once daily. The 30 mg strength is often used for dose reduction or selected patients requiring a lower starting dose.

7. How should Afatinib 30 mg be taken?

Take it orally according to the oncologist’s instructions, generally once daily on an empty stomach.

8. Can Afatinib be taken with food?

Afatinib should generally be taken at least 3 hours after food and at least 1 hour before the next meal.

Product DetailsInformation
Product NameAfatinib 30 mg
Generic NameAfatinib
Active IngredientAfatinib (commonly supplied as afatinib dimaleate)
Strength30 mg
Dosage FormFilm-Coated Oral Tablet
Drug ClassTyrosine Kinase Inhibitor (TKI)
Therapeutic CategoryTargeted Anticancer Medicine
Primary UseSelected EGFR mutation-positive non-small cell lung cancer (NSCLC)
Additional UseSelected previously treated metastatic squamous NSCLC
Mechanism of ActionIrreversible inhibition of ErbB family receptor tyrosine kinases
Administration RouteOral
Reference BrandsGilotrif / Giotrif
ManufacturerVaries by brand; verify product packaging
Pack SizeVerify from product packaging
Prescription StatusPrescription-Only Anticancer Medicine
StorageFollow manufacturer instructions; generally store at controlled room temperature and protect from moisture
Pack sizes28 tablets, 56 tablets, 84 tablets

2 reviews for Afatinib 30 mg

  1. Avery (verified owner) –

    Helped me recover faster from viral infections, amazing product!

  2. Liam (verified owner) –

    Great for daily immune defense, feeling stronger and healthier.

Add a review

Your email address will not be published. Required fields are marked *

Bulk / B2B price inquiry

Tell us what you need and we’ll reply by email.